ClinicalTrials.gg
Not yet recruitingNCT06942767Updated Apr 27, 2025

Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

A Phase 2 interventional study of QLS31905 for Injection and QL2107 Injection in Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma, sponsored by Qilu Pharmaceutical Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-27.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is an open-label, multicenter Phase II clinical study aimed at evaluating the tolerability, safety, efficacy, PK profile, and immunogenicity of QLS31905 for Injection combined with QL2107 Injection and XELOX regimen in the first-line treatment of CLDN18.2-positive unresectable locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Read the detailed description

QLS31905 is a bispecific antibody targeting CD3 and CLDN18.2 independently developed by Qilu Pharmaceutical Co., Ltd.

QL2107 is a biosimilar of pembrolizumab (Keytruda®) developed by Qilu Pharmaceutical Co., Ltd.

This is an open-label, multicenter Phase II clinical study aimed at evaluating the tolerability, safety, efficacy, PK profile, and immunogenicity of QLS31905 for Injection combined with QL2107 Injection and XELOX regimen in the first-line treatment of CLDN18.2-positive unresectable locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

02

Conditions studied

  • Gastric Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma

Browse trials for

Keywords

  • CLDN18.2, gastric or gastroesophageal junction (GEJ) adenocarcinoma
03

In context

Adenocarcinoma

620 studies on the registry are indexed under Adenocarcinoma; 148 are open to participants now.

This study's planned enrollment of 100 is above the median of 57 across 490 interventional studies indexed under Adenocarcinoma.

Browse Adenocarcinoma studies →

Lead sponsor

Qilu Pharmaceutical Co., Ltd. is the lead sponsor of 200 studies on the registry; 122 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with unresectable locally advanced or gastric or gastroesophageal junction (GEJ) adenocarcinoma confirmed by histopathological or cytological examination;
  • Subjects with at least one designated as a target lesion, as assessed by the investigator according to v1.1. Lesions that have received radiotherapy or other local treatments may be considered measurable if they demonstrate imaging PD;
  • No prior systemic anti-tumor treatment for locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Exclusion criteria

Exclusion Criteria:

  • Subjects with a known history of severe or repeated allergy, intolerance, or to QLS31905, QL2107, or other large molecule protein preparations, as well as Oxaliplatin Injection or Capecitabine Tablets and any components in their preparations;
  • Subjects had other second primary within 5 years prior to the first dose;
  • Subjects with hemorrhage within 3 months before the first dose
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    QLS31905+QL2107+ XELOX

    QLS31905+QL2107+ oxaliplatin + capecitabine

    Drug: QLS31905 for Injection · Drug: QL2107 Injection · Drug: Oxaliplatin Injection · Drug: Capecitabine Tablets

Interventions

06

What researchers measure

Primary outcomes

  1. DLT

    Dose Limiting Toxicity,for Dose Escalation Stage

    Time frame: up to 42 days following first dose

  2. MTD

    Maximum Tolerated Dose,for Dose Escalation Stage.

    Time frame: up to 42 days following first dose

  3. ORR (Objective Response Rate)

    ORR is defined as the proportion of participants who have a best overall response of Complete Response (CR) or Partial Response (PR) as assessed by investigator per RECIST 1.1

    Time frame: Approximately 24 months

Secondary outcomes

  1. AE (adverse events)

    AEs are any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Approximately 24 months

  2. Number of anti-drug antibody (ADA) Positive Participants

    Immunogenicity will be measured by the number of participants that are ADA positive.

    Time frame: Approximately 24 months

  3. DOR (Duration of Response)

    DOR is defined as the time from the date of the first response (CR/PR) until the date of radiological progressive disease or death due to any cause (whichever occurs first)

    Time frame: Approximately 24 months

  4. PFS (Progression Free Survival)

    PFS is defined as the duration from the subject's first dose of the investigational product to the first imaging confirmation of radiological progressive disease or death due to any cause (whichever occurs first).

    Time frame: Approximately 24 months

  5. OS (Overall Survival)

    OS is defined as the duration from the first dose of the investigational product to the time point when death occurs due to any cause.

    Time frame: Approximately 24 months

  6. Maximum concentration (Cmax)

    Cmax will be derived from the PK serum samples collected.

    Time frame: Approximately 24 months

  7. Terminal elimination half-life (T1/2)

    T1/2 will be derived from the PK serum samples collected.

    Time frame: Approximately 24 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2025; primary completion for Dec 2026, 18 months later.

Of 93 phase 2 interventional studies under Adenocarcinoma, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 82. This study's planned 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2025
First posted
Apr 24, 2025
StartEst.
Jun 2025
Primary completionEst.
Dec 2026
CompletionEst.
Mar 2028
Last update
Apr 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06942767
Responsible party
Sponsor
First posted
Apr 24, 2025
Start date
Jun 2025 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Mar 2028 (estimated)
Last update
Apr 27, 2025

Study contacts

Lin Shen, PHD
Contact
linshenpku@163.com
010-881965671

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905

Start the discussion